International Journal of Health Systems and Medical Sciences
ISSN: 2833-7433
Volume 05 Number 03 (2026)
Impact Factor: 10.87
SJIF (2023): 3.656

www.inter-publishing.com

Article

Human Bocavirus: Epidemiology, Pathogenesis, Diagnosis, and Clinical Implications

Fatima Moeen Abbas

1. College of Science for Women, Biology Dept, University of Babylon, Iraq
* Correspondence: wsci.fatima.m@uobabylon.edu.iq

Abstract: Human Bocavirus (HBoV), a member of the Parvoviridae family, has emerged as a notable viral agent implicated in respiratory and gastrointestinal infections, primarily affecting pediatric populations. Since its discovery in 2005, four genotypes (HBoV1 to HBoV4) have been identified, with HBoV1 predominantly associated with upper and lower respiratory tract illnesses, whereas HBoV2–4 are more frequently detected in fecal specimens and linked to gastrointestinal symptoms. The high rate of coinfection with other respiratory or enteric viruses has challenged the understanding of its direct pathogenic role. Current diagnostic approaches rely heavily on real-time polymerase chain reaction (RT-PCR), which offers high sensitivity and specificity, though serological assays and antigen detection methods are increasingly being explored. Therapeutic interventions remain limited to supportive care, and no antiviral agents or vaccines have been approved to date. This review consolidates current knowledge on the molecular characteristics, transmission dynamics, host immune responses, clinical relevance, diagnostic modalities, and potential therapeutic targets related to human bocavirus infection.

Keywords: Human Bocavirus; Parvovirus; Respiratory Tract Infections; Gastroenteritis; Molecular Diagnosis; Pediatric Virology

Citation: Abbas, F. M. Human Bocavirus: Epidemiology, Pathogenesis, Diagnosis, and Clinical Implications. International Journal of Health Systems and Medical Sciences 2026, 5(3), 41-56

Received: 10th Mar 2026
Revised: 21th Apr 2026
Accepted: 08th May 2026
Published: 20th June 2026

1. Introduction

Human Bocavirus (HBoV) was first identified in 2005 from nasopharyngeal aspirates of children presenting with acute respiratory illness in Sweden. It belongs to the genus *Bocaparvovirus*, subfamily *Parvovirinae*, within the family *Parvoviridae*. The name "bocavirus" is derived from its genetic similarity to bovine parvovirus and canine minute virus. The genome is a single-stranded DNA molecule of approximately 5.2 kb, containing three major open reading frames encoding the nonstructural proteins NS1 and NP1, and the structural protein VP1 [1],[2]. Since its discovery, HBoV has been detected worldwide with a relatively high prevalence in young children, and is associated with acute respiratory and gastrointestinal diseases [3],[4].

HBoV is a non-enveloped, single-stranded DNA virus with a genome size of approximately 5.3 kilobases. It encodes three open reading frames (ORFs): the nonstructural proteins (NS1 and NP1) and the structural capsid proteins (VP1 and VP2). Four genotypes have been described: HBoV1, HBoV2, HBoV3, and HBoV4. HBoV1 is frequently detected in respiratory secretions, while HBoV2 to HBoV4 are more common in stool specimens and associated with gastroenteritis. HBoV1 is the most prevalent species, especially in respiratory samples, and thus is believed to be the primary cause of respiratory diseases. However, the exact pathogenic role of HBoV is complicated by frequent co-detection with other respiratory viruses. Virion entry into host cells is thought

to be mediated by specific cellular receptors, which remain largely uncharacterized, subsequent to which the virus traffics to the nucleus where its replication occurs, mirroring the replication strategy of other parvoviruses; this process is dependent on host cell DNA polymerases for genome amplification. Notably, HBoV1 demonstrates a pronounced tropism for respiratory epithelial cells, evidenced by its frequent detection in respiratory tract infections; however, the intricacies of the molecular mechanisms underpinning this selective cellular targeting and the subsequent cascade of events leading to pathogenesis remain an area requiring thorough investigation to fully elucidate the virus-host interaction [5].

Epidemiological surveillance data indicate that HBoV infection is globally distributed, with the highest burden observed in children under five years of age. Transmission is believed to occur through respiratory droplets, contact with contaminated surfaces, or fecal-oral routes. Viral shedding may persist for extended periods, raising questions about its role in asymptomatic carriage and recurrent detection. The incidence of HBoV infections demonstrates a distinct seasonal pattern, peaking during the colder months of the year, a trend consistent with several other respiratory viruses, and this may be related to environmental conditions that favor viral survival and transmission, as well as host factors such as decreased immune function due to reduced exposure to sunlight and vitamin D [6].

HBoV has been frequently co-detected with other respiratory and enteric pathogens, which complicates its attribution as a primary etiologic agent. However, increasing evidence from viral load studies, seroconversion analyses, and animal models suggests a direct pathogenic role, particularly for HBoV1 in acute respiratory illness. Clinical manifestations of HBoV infection are broad, ranging from mild upper respiratory tract symptoms to severe pneumonia and bronchiolitis. Gastrointestinal symptoms, such as diarrhea and vomiting, have also been reported, particularly in association with HBoV2–4. In immunocompromised patients, HBoV infections may present with more severe and prolonged symptoms, thus underscoring the need for vigilance in susceptible populations. Clinical manifestations of HBoV infection are broad, ranging from mild upper respiratory tract symptoms to severe pneumonia and bronchiolitis.

Understanding the viral structure, genomic organization, and replication strategy of HBoV is critical for improving diagnostic accuracy and for the development of targeted antiviral strategies. Table 1 summarizes the genome structure and functional roles of HBoV-encoded proteins. Diagnostic assays based on real-time PCR have enabled rapid and sensitive detection of HBoV in clinical samples. Given the current absence of specific antiviral interventions targeting HBoV infections, clinical management strategies primarily focus on supportive care, with the aim of alleviating symptoms and effectively managing any secondary complications; despite these limitations, a more comprehensive elucidation of the molecular mechanisms that govern viral replication processes, cellular entry pathways, and the sophisticated strategies employed by the virus to evade host immune responses is essential, and promises to unveil potential targets for therapeutic intervention, including inhibitors designed to disrupt viral DNA replication, capsid assembly dynamics, or critical host-virus protein interactions.[7]

Table 1. Genomic Organization and Functional Proteins of Human Bocavirus

Gene (ORF)	Protein	Function
ORF1	NS1 (Non-Structural Protein 1)	Involved in viral replication, helicase and endonuclease activity
ORF2	NP1 (Nuclear Phosphoprotein 1)	Regulates mRNA processing; essential for expression of capsid proteins

ORF3	VP1 and VP2 (Viral Proteins)	Structural proteins forming the viral capsid; VP1 includes a unique region (VP1u) with phospholipase A2 activity

Epidemiology

Since its discovery, Human Bocavirus (HBoV) has been identified across diverse geographic regions, affecting individuals of all age groups. However, the infection predominantly affects infants and young children under the age of five, with peak incidence between 6 and 24 months. Detection rates in symptomatic pediatric respiratory tract samples range from 2% to 19% depending on location, season, diagnostic method, and sample type. The exact modes of transmission remain an area of active investigation. However, the virus is thought to spread through close contact with respiratory secretions, such as droplets produced during coughing or sneezing, similar to other common respiratory viruses. Fomite transmission via contaminated surfaces may also contribute, given the demonstrated environmental stability of parvoviruses, and the possibility of fecal-oral transmission has been suggested based on the detection of HBoV in stool samples, mainly for HBoV-2 [8].

Age Distribution

a. HBoV1 is commonly isolated from nasopharyngeal aspirates and bronchoalveolar lavage fluid in hospitalized children with acute lower respiratory tract infections (ALRTIs), including bronchiolitis, pneumonia, and wheezing.[9]
b. Seroprevalence studies indicate that by the age of five, over 90% of children have been exposed to HBoV1.[10]
c. HBoV2–4 are more frequently detected in stool samples and associated with gastroenteritis, although their exact role remains less defined.[11]

Seasonality

a. HBoV1 shows a seasonal pattern similar to other respiratory viruses, with higher prevalence during late autumn and winter in temperate climates.
b. Detection in tropical regions shows year-round circulation with smaller seasonal fluctuations
c. Increased rates during winter months coincide with periods of higher incidence of other respiratory infections like RSV and influenza.

The global prevalence of Human Bocavirus exhibits considerable variation, influenced by factors such as geographic location, climate, population density, and socioeconomic status. Limited data is available about the incidence of HBoV in places such as Egypt [12].

Coinfections

a. High rates of coinfection with other respiratory viruses are reported, especially with Respiratory Syncytial Virus (RSV), adenovirus, rhinovirus, and human metapneumovirus.
b. Coinfection complicates the interpretation of clinical significance, although higher HBoV viral loads in mono-infected individuals have been associated with more severe disease.
c. Bacterial coinfections, particularly with Streptococcus pneumoniae and Haemophilus influenzae, have also been observed in some studies [13].

Geographic Distribution and Burden

a. Studies from Europe, Asia, Africa, and the Americas confirm the widespread circulation of HBoV.
b. HBoV is increasingly recognized as a contributor to hospitalization due to respiratory or diarrheal illness in early childhood.

c. HBoV DNA has also been detected in adults, but usually at lower frequency and often in immunocompromised patients or individuals with chronic respiratory conditions.
d. The transmission of HBoV is most likely to occur via the fecal-oral and respiratory routes [14].

Table 2. Global Detection Rates and Distribution of HBoV by Region

Region	Sample Type	Median Detection Rate (%)	Age Group Most Affected	Predominant Genotype
North America	Nasopharyngeal swabs	3–7%	<2 years	HBoV1
Europe	Respiratory samples	4–10%	<5 years	HBoV1
Asia	Stool + respiratory	5–15%	<3 years	HBoV1–HBoV3
Middle East	Respiratory swabs	2–6%	Infants	HBoV1
Sub-Saharan Africa	Fecal samples	6–12%	Under 5	HBoV2–HBoV4
Latin America	Nasopharyngeal/stool	3–9%	<2 years	HBoV1 and HBoV2

Molecular Biology And Genetic Diversity Of Human Bocavirus

Human Bocavirus (HBoV) is a small, non-enveloped virus possessing a linear, single-stranded DNA genome approximately 5.3 kilobases in length. It belongs to the genus *Bocaparvovirus*, within the subfamily *Parvovirinae* of the *Parvoviridae* family. The virus shares significant sequence homology with bovine parvovirus and canine minute virus, both of which informed the naming and classification of the human species. The HBoV genome encodes for four major open reading frames that code for both structural and non-structural proteins crucial for viral replication and pathogenesis.[15],

Genomic Structure and Organization

The HBoV genome consists of three major open reading frames (ORFs):

a. **ORF1** encodes the large non-structural protein NS1, which plays a crucial role in viral replication, DNA binding, helicase activity, and induction of host cell apoptosis.
b. **ORF2** encodes NP1, a unique non-structural nuclear phosphoprotein, absent in other parvoviruses. NP1 is essential for the processing of pre-mRNA and plays a critical role in splicing and expression of structural genes.
c. **ORF3** encodes two capsid proteins, VP1 and VP2. VP1 contains a unique N-terminal extension (VP1u) that exhibits phospholipase A2 (PLA2) activity, required for endosomal escape during viral entry. VP2 forms the majority of the viral capsid.

Despite their compact size, HBoV genomes also include palindromic terminal sequences that form secondary structures critical for replication initiation. These features are consistent with other members of the *Parvoviridae* family[16]

Genotypic Classification

To date, four genotypes of HBoV have been identified based on phylogenetic analyses:

a. **HBoV1** is predominantly associated with respiratory tract infections.
b. **HBoV2**, **HBoV3**, and **HBoV4** are mainly found in fecal samples and are proposed to be enteric types.

Sequence identity among the four genotypes varies considerably:

a. HBoV1 and HBoV3 share approximately 76–78% nucleotide similarity.
b. HBoV2 and HBoV4 are more closely related to each other, sharing over 90% nucleotide identity, particularly in the VP1/VP2 region.

These distinctions suggest independent evolutionary lineages and possible differences in tissue tropism, pathogenesis, and immune response.[17]

Mutation Dynamics and Genetic Drift

As a single-stranded DNA virus, HBoV is relatively stable compared to RNA viruses. However, limited proofreading during replication still permits nucleotide substitutions, especially within the capsid gene regions. Several studies have documented the presence of quasispecies and intra-host variation, particularly in immunocompromised patients or those with persistent infections.

Key observations:

a. The VP1u region is hypervariable and considered a major site for antigenic diversity.
b. Recombination events have been observed between HBoV2 and HBoV4, especially in the non-structural gene region, suggesting that genetic exchange may contribute to the emergence of novel variants.

These genetic features influence viral fitness, transmission efficiency, host range, and immune escape mechanisms. Evolutionary pressure from host immune responses may select for adaptive mutations in antigenic regions, especially in populations with high seroprevalence.[18]

2. Materials and Methods

Evolutionary Considerations

Molecular clock analyses suggest that the divergence of HBoV from ancestral animal parvoviruses occurred several hundred years ago. However, HBoV's clinical relevance became apparent only after the development of sensitive molecular diagnostic tools.

Whole-genome sequencing of HBoV isolates from various geographical locations reveals considerable conservation in the NS1 and NP1 genes, while the VP1/VP2 region shows genotype-specific mutations. This pattern supports the hypothesis that structural proteins undergo immune-driven selection, while non-structural regions remain under functional constraint.

Phylogenetic trees constructed from global HBoV strains indicate that:

a. HBoV1 has limited genetic divergence and circulates as a relatively stable lineage.
b. HBoV2 and HBoV4 demonstrate more genetic variability, particularly in regions associated with gastrointestinal replication.

The existence of multiple genotypes with distinct tropisms and variable genetic drift underscores the importance of ongoing genomic surveillance.

Table 3. Comparison of Genomic and Biological Characteristics of HBoV Genotypes

Feature	HBoV1	HBoV2	HBoV3	HBoV4
First Identified	2005 (Sweden)	2009 (Pakistan)	2009 (Australia)	2010 (Nigeria)
Main Sample Source	Respiratory tract	Feces	Feces	Feces
Tropism	Respiratory epithelium	Enterocytes	Enterocytes	Enterocytes
Associated Disease	Bronchiolitis, pneumonia	Gastroenteritis	Gastroenteritis	Gastroenteritis
Genome Length (kb)	~5.3	~5.3	~5.3	~5.3
NS1 Identity vs HBoV1	100%	~82%	~78%	~80%

VP1 Identity vs HBoV1	100%	~77%	~76%	~74%
Coinfection Frequency	High	High	Moderate	Moderate

Pathogenesis and Immunological Response of Human Bocavirus

The pathogenic mechanisms of Human Bocavirus (HBoV) remain incompletely defined due to challenges in establishing a robust in vitro culture system and lack of suitable animal models. However, accumulating molecular and histological data from clinical and experimental studies provide insights into viral replication, host immune interaction, and cellular injury patterns. In general, HBoV is believed to be relatively conserved in NS1 and NP1 but more diverse in VP1 and VP2 [19].

Viral Entry and Cellular Tropism

HBoV1 primarily targets the respiratory epithelium, while HBoV2–4 are more commonly associated with enteric tissues. The specific cellular receptor for HBoV remains unidentified, although glycosaminoglycans (GAGs), sialic acid-containing glycans, and potentially unidentified coreceptors may facilitate viral attachment and entry. HBoV1 infects well-differentiated human airway epithelial cells [20].

After binding to host receptors, the virus undergoes endocytosis, followed by endosomal escape. The phospholipase A2 (PLA2) activity of the VP1 unique region (VP1u) is critical for breaching the endosomal membrane. The single-stranded viral DNA is then translocated to the nucleus, where replication and transcription occur using host DNA polymerases during the S phase. HBoV1 also expresses viral non-coding RNA and three structural proteins VP1, VP2, and VP3.

Replication follows a rolling-hairpin mechanism, typical of parvoviruses, producing double-stranded DNA intermediates. These are transcribed into mRNAs encoding non-structural and capsid proteins, which are later assembled into progeny virions.



Figure 1. Proposed replication cycle and pathogenesis of HBoV in respiratory epithelial cells. [21]

Immune Activation and Evasion

HBoV infection activates both innate and adaptive immune responses. Infected cells release pro-inflammatory cytokines including IL-6, IL-8, TNF-α, and interferons (IFN-α/β), promoting the recruitment of neutrophils and macrophages to the site of infection.

However, HBoV appears to suppress effective viral clearance in some patients:

a. Studies show prolonged viral shedding for several weeks post-infection, suggesting incomplete or delayed immune resolution.

b. In vitro models reveal downregulation of type I interferon responses and altered antigen presentation, likely contributing to viral persistence.

Seroconversion studies show that primary HBoV1 infection induces both IgM and IgG responses, particularly targeting the VP2 capsid protein. However, immunity may be short-lived or incomplete, as reinfections and sequential detection of different genotypes have been documented.

The role of cytotoxic T cells in controlling HBoV infection is still under investigation. Limited data suggest that HBoV-specific CD8+ T cells can recognize infected cells, but their contribution to viral clearance and immunopathology requires further study. NS1 has regulatory functions, including transactivation or induction of apoptosis [22].

Histopathological Findings

Autopsy and biopsy studies in fatal or severe cases have reported:

a. Ciliated epithelial cell necrosis
b. Goblet cell hyperplasia
c. Infiltration of mononuclear cells in the lamina propria
d. Desquamation of respiratory epithelial layers

In enteric infections (HBoV2–4), mucosal inflammation, crypt atrophy, and lymphoid hyperplasia have been noted. However, these findings often occur in the context of coinfections, limiting causality attribution.Thus, the precise mechanisms by which HBoV causes tissue damage and respiratory dysfunction remain complex and multifactorial.Studies show that HBoV is associated with both upper and lower respiratory tract infections.

Chronic and Systemic Involvement

HBoV DNA has been detected in extrapulmonary sites such as blood, cerebrospinal fluid, myocardium, and lymph nodes, especially in immunocompromised patients. While the clinical significance remains uncertain, these findings raise concerns about potential viremia and systemic dissemination. In the pediatric age group, HBoV was found in 4.5% of the patients and higher in children between the ages of 1 and 5 [23].

Clinical Presentation and Disease Associations of Human Bocavirus

Human Bocavirus (HBoV) is associated with a broad spectrum of clinical manifestations, most frequently involving the respiratory and gastrointestinal systems. While HBoV1 is primarily linked to acute respiratory tract infections (ARTIs), HBoV2–4 have been identified in patients with gastroenteritis. The majority of infections occur in children, although adult and immunocompromised populations may also be affected.[24]

Respiratory Tract Infections

HBoV1 is frequently detected in hospitalized children with lower respiratory tract involvement. Common clinical features include:

a. Cough (dry or productive)
b. Rhinorrhea
c. Fever
d. Wheezing
e. Dyspnea
f. Hypoxia (in moderate to severe cases)

In some children, HBoV1 infection progresses to:

a. Bronchiolitis
b. Pneumonia
c. Asthma-like exacerbations

Clinical severity is often influenced by coinfection with viruses such as RSV, adenovirus, and influenza. Patients with high viral loads and absence of co-pathogens are more likely to exhibit severe symptoms, indicating a direct pathogenic role. Other reported signs and symptoms of HBoV include vomiting, diarrhea, hypoxemia and tachypnea.

Gastrointestinal Manifestations

HBoV2, HBoV3, and HBoV4 have been detected in stool samples of patients with:

a. Acute non-bloody diarrhea
b. Vomiting
c. Low-grade fever
d. Abdominal pain

These genotypes are less frequently found in respiratory samples. Their causative role in gastroenteritis is still under investigation due to high co-detection rates with norovirus, rotavirus, and enteric adenoviruses. The detection rate of HBoV in fecal samples from children with acute gastroenteritis was 10.1%.

Other Clinical Associations

While data remain limited, HBoV DNA has also been reported in:

a. **Serum or whole blood** (viremia in acute phase)
b. **Cerebrospinal fluid (CSF)** (in rare encephalitis cases)
c. **Pericardial fluid and myocardial biopsies** (suggesting possible involvement in myocarditis)

Chronic detection in nasopharyngeal swabs and stool specimens has been documented, sometimes for over one month. This may reflect prolonged viral shedding or low-level persistence. Although frequently detected in children with respiratory infections, its direct pathogenic role is sometimes debated, particularly due to high rates of viral co-detection. HBoV1 was initially discovered in 2005 in nasopharyngeal aspirates from children experiencing acute respiratory tract infections [25].

Severity Spectrum

a. **Mild cases**: Self-limiting upper respiratory symptoms or watery diarrhea
b. **Moderate cases**: Bronchitis or gastroenteritis with dehydration
c. **Severe cases**: Hospitalization due to pneumonia, respiratory distress, or persistent vomiting and diarrhea

Risk factors for severe disease include:

a. Age <24 months
b. Premature birth
c. Underlying cardiac or pulmonary disease
d. Immunodeficiency (congenital or acquired)

Coinfection and Disease Modulation

a. Coinfections are found in >60% of HBoV-positive respiratory samples.
b. Clinical outcomes often depend on the type and number of co-pathogens.
c. In some cases, HBoV may act as a secondary pathogen, exacerbating symptoms initiated by another virus.

Diagnostic Clues from Clinical Presentation

a. Persistent wheezing in young children unresponsive to standard bronchodilators
b. Diarrhea in infants with no rotavirus or adenovirus detection
c. Detection of HBoV1 in high viral loads (>10^4–10^6 copies/mL) in nasopharyngeal samples is considered supportive of primary infection

3. Results

Diagnostic Techniques for Human Bocavirus Detection

Accurate diagnosis of Human Bocavirus (HBoV) infection remains challenging due to its high rate of coinfection, prolonged shedding, and absence of standardized testing algorithms. Molecular diagnostics form the foundation of HBoV detection, with nucleic acid amplification tests being the most widely used. Other methods—including serological assays, antigen detection, and next-generation sequencing (NGS)—play complementary roles in research and epidemiology.[26]

1. Real-Time PCR (qPCR) and Conventional PCR

Real-time PCR targeting conserved regions of the NS1 or NP1 genes is the gold standard for HBoV detection. It allows quantification of viral load and differentiation among genotypes when combined with type-specific probes.

a. High sensitivity (10–100 copies/reaction)
b. High specificity with genotype discrimination
c. Can detect persistent low-level shedding
d. Often included in multiplex respiratory or enteric viral panels

Limitations

a. Cannot distinguish active infection from residual viral DNA
b. Requires expensive reagents and equipment
c. Limited access in low-resource settings

2. Serological Assays

Serology (IgM and IgG) is useful for assessing recent or past infection, particularly in seroprevalence studies. ELISA tests using recombinant VP2 protein have demonstrated diagnostic value.

a. **IgM positivity** suggests recent infection
b. **IgG seroconversion** between acute and convalescent samples confirms primary infection

Limitations

a. Antibodies may take days to weeks to appear
b. Cross-reactivity between HBoV genotypes may occur
c. Not suitable for early diagnosis in acute illness

3. Antigen Detection

Few antigen-detection assays for HBoV are commercially available. Some research-grade monoclonal antibody-based tests targeting VP2 or VP1 capsid proteins have shown promise.

a. Rapid and inexpensive
b. Suitable for point-of-care settings
c. Useful for epidemiological screening

Limitations

a. Low sensitivity, especially in adults
b. Lack of standardization and regulatory approval

4. Next-Generation Sequencing (NGS)

NGS provides comprehensive insights into HBoV genomics, coinfections, and mutation dynamics. Whole-genome sequencing enables identification of novel strains and recombination events.[27]

a. Unbiased detection of all HBoV genotypes and coinfectionsDetects known and emerging genotypes
b. Useful for outbreak investigations
c. Allows study of viral evolution

Limitations

a. High cost and complex bioinformatics
b. Not routinely used in clinical diagnostics

5. In Situ Hybridization and Immunohistochemistry

Applied primarily in autopsy or biopsy specimens, these methods allow localization of viral RNA or proteins in tissue. They contribute to understanding of tissue tropism and pathogenesis.[28]

a. Helpful in research settings
b. Not used in routine diagnostics

Sample Types for Diagnostic Testing

Sample type affects sensitivity. Proper collection and timing are critical. Table 4 summarizes optimal sample choices.

Table 4. Diagnostic Methods and Respiratory/Gastrointestinal Sample Considerations

Diagnostic Method	Target	Sample Type(s)	Strengths	Limitations
qPCR (Real-time PCR)	HBoV DNA (NS1/NP1)	Nasopharyngeal swab, stool, blood	High sensitivity, quantification	Cannot confirm active replication
Conventional PCR	HBoV DNA	Same as above	Genotype identification possible	Less quantitative
ELISA (IgM/IgG)	Antibodies	Serum	Identifies recent or past infection	Delayed seroconversion
Antigen Detection Assay	VP1/VP2 Proteins	NP swab, stool	Rapid results, low cost	Low sensitivity, not widely available
NGS	Whole genome	Any nucleic acid-containing sample	Strain typing, coinfection profiling	High cost, not suitable for diagnosis
In Situ Hybridization	Viral RNA	Tissue biopsy	Research, localizes virus in tissue	Not routine

TREATMENT STRATEGIES AND ONGOING THERAPEUTIC RESEARCH FOR HUMAN BOCAVIRUS

To date, there are no licensed antiviral agents or vaccines specifically targeting Human Bocavirus (HBoV). Clinical management remains largely supportive and symptomatic. However, growing interest in its pathogenic role has stimulated research into potential therapeutic interventions including monoclonal antibodies, antiviral candidates, immunomodulatory strategies, and preventive vaccine platforms.[29]

1. Supportive Management

Most HBoV infections are self-limiting, particularly in immunocompetent hosts. Supportive therapy is the mainstay of clinical care.

Respiratory Infections:

a. **Oxygen therapy** for hypoxia or respiratory distress
b. **Bronchodilators** for wheezing episodes (though data supporting their efficacy in HBoV is limited)
c. **Intravenous fluids** to prevent dehydration in hospitalized patients
d. **Antipyretics and analgesics** to manage fever and discomfort

Gastrointestinal Symptoms:

a. **Oral rehydration therapy** for mild diarrhea
b. **Intravenous rehydration** in cases of moderate to severe dehydration
c. **Zinc supplementation** may be considered, especially in malnourished children

Despite frequent use, **corticosteroids** and **antibiotics** are not recommended unless there is clinical or microbiological evidence of bacterial superinfection or coexisting conditions such as asthma exacerbation.[30]

2. Antiviral Agents: Preclinical Insights

Unlike other respiratory viruses such as influenza or RSV, no specific antiviral has been approved for HBoV. Several antiviral strategies have shown experimental promise:

A. NUCLEOTIDE ANALOGUES

Agents like **cidofovir**, used in treating other DNA viruses (e.g., adenovirus, CMV), have been proposed but not formally tested against HBoV in clinical trials.[31]

a. In vitro inhibition of parvovirus replication has been demonstrated with selected nucleoside analogues.
b. Toxicity and off-target effects remain concerns for systemic use.

B. RNA INTERFERENCE (RNAI)

Small interfering RNAs (siRNAs) targeting HBoV NS1 and NP1 genes have successfully reduced viral replication in transfected cell lines.[32]

a. Potent and specific inhibition in vitro
b. Delivery and in vivo stability limit clinical applicability

3. Monoclonal Antibodies (mAbs)

The VP2 capsid protein is the main immunogenic component of HBoV. Neutralizing antibodies directed against conformational epitopes on VP2 have shown protective effects in experimental models.

a. **Recombinant humanized mAbs** have been engineered against parvoviral structural proteins.
b. Some studies show cross-neutralization among genotypes, especially between HBoV1 and HBoV3.

Passive immunotherapy may be a viable adjunct in immunocompromised patients with persistent or severe HBoV infection, although no such strategy is clinically available at this time.

4. Immunoglobulin Therapy (IVIG)

Intravenous immunoglobulin (IVIG) products have been used in select cases involving immunosuppressed patients with high HBoV DNAemia or prolonged symptoms.[33]

a. IVIG preparations often contain anti-HBoV IgG from seropositive donors.
b. Case reports describe clinical improvement and viral clearance following administration.
c. Controlled studies are lacking, and the exact mechanism of benefit is unclear.

5. Vaccine Development: Theoretical and Experimental Approaches

No commercial vaccine against HBoV is under development or clinical trial. However, several theoretical platforms are being explored:

A. VIRUS-LIKE PARTICLES (VLPS)

a. Recombinant expression of VP2 proteins has led to self-assembling VLPs that mimic the native virion.
b. Animal immunization studies using VLPs have demonstrated the induction of neutralizing antibodies and mucosal immune responses.

B. DNA VACCINES

a. Plasmid vectors expressing the NS1 or VP1/VP2 genes have been proposed as a platform for DNA-based vaccination.
b. These constructs are in preclinical stages and require optimization for delivery and immunogenicity.

C. LIVE-ATTENUATED VECTORS

a. There is interest in incorporating HBoV capsid antigens into replication-deficient adenoviral vectors or measles virus backbones.
b. These may stimulate both humoral and cellular immunity but pose theoretical risks in immunocompromised hosts.

6. Challenges in Therapeutic Development

a. **Persistent shedding** complicates the differentiation of active versus past infection in clinical trials.
b. **Lack of animal models** hinders evaluation of pathogenicity and drug efficacy in vivo.
c. **High coinfection rates** may obscure clinical endpoints in antiviral or vaccine studies.
d. **Unidentified cellular receptor(s)** and incomplete replication models limit mechanistic studies.

Table 5. Summary of Current and Investigational Therapeutic Approaches for HBoV

Strategy	Target/Mechanism	Development Status	Challenges
Supportive care	Symptomatic relief	Clinical standard	No impact on viral replication
IVIG	Passive immunotherapy	Case-based use	Limited availability, inconsistent response
Monoclonal antibodies	Neutralization of VP1/VP2	Preclinical	Genotype variability, cost
Nucleotide analogues	DNA polymerase inhibition (e.g., cidofovir)	Experimental	Toxicity, no human data
RNA interference	siRNA against NS1/NP1	In vitro	Delivery barriers, transient effect
Virus-like particle vaccines	VP2-induced immune response	Animal studies	Stability, scalability, regulatory approval
DNA vaccines	Plasmid-based antigen expression	Early preclinical	Low immunogenicity without adjuvants

4. Discussion

PREVENTION, INFECTION CONTROL, AND PUBLIC HEALTH CONSIDERATIONS

Human Bocavirus (HBoV), particularly HBoV1, is increasingly detected in clinical settings. Although a definitive causative role in all cases remains under investigation, its potential for transmission—especially in pediatric and immunocompromised populations—demands structured preventive measures and heightened public health awareness.[34]

1. Transmission Pathways

HBoV is presumed to be transmitted via:

a. **Respiratory droplets** from coughing or sneezing
b. **Direct contact** with contaminated hands or surfaces
c. **Fecal–oral route**, particularly for genotypes HBoV2–4

Viral DNA has been identified in both respiratory and fecal samples, as well as environmental surfaces in healthcare settings, confirming the plausibility of multiple routes of transmission.

2. Nosocomial Spread and Infection Control

HBoV has been implicated in outbreaks in neonatal intensive care units and pediatric wards, often in association with other respiratory viruses. Because of its ability to persist in the upper respiratory tract, asymptomatic or subclinical carriers may contribute to silent transmission. [35]

Recommended infection control measures:

a. **Droplet and contact precautions** for hospitalized children with HBoV-positive respiratory illness
b. **Isolation or cohorting** of infected patients during hospitalization
c. **Hand hygiene protocols** for healthcare workers and visitors
d. **Environmental disinfection** focusing on high-touch surfaces and shared medical equipment

Duration of isolation is typically aligned with symptom resolution, though some suggest maintaining precautions for up to 2 weeks due to prolonged shedding.

3. Community-Based Prevention

Community-level interventions are similar to those recommended for other respiratory and enteric viruses:

a. **Handwashing** with soap and water, especially after nose-blowing or diaper changes

b. **Avoiding close contact** with symptomatic individuals
c. **Use of tissues or elbow cover** during coughing or sneezing
d. **Disinfection of shared toys, surfaces, and household items** in child-care environments

In child-care centers and schools, outbreaks of viral gastroenteritis or respiratory illness should prompt temporary class cohorting and enhanced sanitation.

4. Surveillance and Reporting Gaps

Despite its global distribution, HBoV is not a notifiable disease in most countries. This limits the availability of reliable incidence data and hinders public health planning.[36]

Key limitations in current surveillance:

a. **Inconsistent testing practices** across institutions
b. **Lack of routine HBoV inclusion** in viral panel diagnostics
c. **Underrecognition of non-respiratory presentations**

Targeted surveillance in pediatric populations, immunocompromised hosts, and settings with high respiratory or diarrheal disease burden is warranted. Integrating HBoV detection into multiplex respiratory panels may improve detection rates and clarify its epidemiological footprint.

5. Need for Public Health Guidelines

Given the detection of HBoV in hospital outbreaks and its association with severe disease in vulnerable populations, standardized guidelines are necessary. These should include:

a. Criteria for laboratory testing
b. Management protocols for high-risk patients
c. Reporting systems for cluster cases
d. Recommendations for sample storage and genomic data sharing

Table 6. Summary of Infection Control and Prevention Practices for HBoV

Setting	Recommended Measures	Justification
Hospitals	Droplet/contact precautions, isolation, hand hygiene	Prevent nosocomial spread
Households	Handwashing, cough etiquette, surface disinfection	Limit intra-family transmission
Child-care centers	Exclusion of symptomatic children, enhanced sanitation	Reduce outbreak risk
Immunocompromised units	Testing on admission, prolonged isolation if positive	Prevent complications from persistent shedding
Laboratories	Sample containment, nucleic acid disposal precautions	Avoid contamination in molecular diagnostics

5. Conclusion

Human bocavirus has gained recognition as a widespread viral agent impacting human health, particularly manifesting as respiratory and gastrointestinal morbidities predominantly affecting the pediatric demographic. The concurrent presence of HBoV with other respiratory and enteric pathogens obfuscates the precise determination of its singular pathogenic role in complex clinical scenarios, warranting further investigation to elucidate its specific contribution to disease manifestation. The observed genetic diversity across HBoV species introduces substantial complexity into the virus's epidemiological behavior, potentially leading to variations in clinical manifestations and influencing the effectiveness of current diagnostic and therapeutic strategies. Sophisticated molecular methodologies, including next-generation sequencing and quantitative real-time polymerase chain reaction (qRT-PCR) assays, have revolutionized the detection and characterization of HBoV strains, providing high-resolution insights into their evolutionary trajectories and global dissemination patterns. While the diagnostic

relevance of HBoV is complicated by its frequent detection in both symptomatic and asymptomatic individuals, the consistent association of HBoV with severe lower respiratory tract infections, particularly among vulnerable pediatric populations, reinforces the critical importance of enhanced clinical awareness alongside the judicious and evidence-based implementation of therapeutic interventions. The initial challenge in ascribing a definitive pathogenic role to HBoV1 stemmed from its frequent detection in asymptomatic individuals and its propensity for co-infection with other respiratory viruses, thereby complicating the process of establishing clear and unambiguous clinical diagnoses. However, a convergence of evidence derived from controlled clinical studies and refined experimental paradigms now supports the assertion that HBoV1 possesses the intrinsic capacity to function as an autonomous etiologic agent in the context of respiratory illnesses, capable of eliciting a diverse array of clinical symptoms even in the absence of concomitant viral pathogens; moreover, documented cases of HBoV1 mono-infection have exhibited a definitive correlation with the subsequent development of severe lower respiratory tract infections, frequently necessitating the implementation of advanced respiratory support modalities and intensive care interventions.

REFERENCES

[1] S. Alvarez-Munoz, N. Upegui-Porras, A. P. Gómez, and G. Ramírez, "Key factors that enable the pandemic potential of RNA viruses and inter-species transmission: A systematic review," *Viruses*, vol. 13, no. 4, Art. no. 537, 2021, doi: 10.3390/v13040537.

[2] A. Bakır, N. Karabulut, S. Alaçam, S. Meşe, A. Somer, and A. Ağaçfidan, "Investigation of human bocavirus in pediatric patients with respiratory tract infection," *The Journal of Infection in Developing Countries*, vol. 14, no. 10, p. 1191, 2020, doi: 10.3855/jidc.12553.

[3] C. Calvo, M. L. García-García, F. Pozo, D. Carballo, E. Martínez-Monteserín, and I. Casas, "Infections and coinfections by respiratory human bocavirus during eight seasons in hospitalized children," *Journal of Medical Virology*, vol. 88, no. 12, p. 2052, 2016, doi: 10.1002/jmv.24562.

[4] D. Daka, G. Hailemeskel, and D. A. Fenta, "Seroprevalence of Hepatitis B virus and associated factors among female sex workers using respondent-driven sampling in Hawassa City, Ethiopia," *Infection and Drug Resistance*, pp. 4301–4309, 2021, doi: 10.2147/IDR.S332333.

[5] R. De, K. Zhang, F. Wang, *et al.*, "Human bocavirus 1 is a genuine pathogen for acute respiratory tract infection in pediatric patients determined by nucleic acid, antigen, and serology tests," *Frontiers in Microbiology*, vol. 13, 2022, doi: 10.3389/fmicb.2022.932858.

[6] E. Eyzaguirre, D. H. Walker, and S. R. Zaki, "Immunohistology of infectious diseases," in *Elsevier eBooks*. Elsevier BV, 2006, p. 43, doi: 10.1016/B978-0-443-06652-8.50008-9.

[7] J. Fakhiri, K. P. Linse, M. Mietzsch, *et al.*, "Impact of natural or synthetic singletons in the capsid of human bocavirus 1 on particle infectivity and immunoreactivity," *Journal of Virology*, vol. 94, no. 11, 2020, doi: 10.1128/JVI.00170-20.

[8] B. Göktürk, "Successful therapy with intravenous gamma globulin in two children with postinfectious bronchiolitis obliterans," *Journal of Pulmonology and Respiratory Research*, vol. 1, no. 1, p. 9, 2017, doi: 10.29328/journal.jprr.1001003.

[9] M. Guido, M. R. Tumolo, T. Verri, *et al.*, "Human bocavirus: Current knowledge and future challenges," *World Journal of Gastroenterology*, vol. 22, no. 39, p. 8684, 2016, doi: 10.3748/wjg.v22.i39.8684.

[10] C. M. Harrison, J. M. Doster, E. H. Landwehr, *et al.*, "Evaluating the virology and evolution of seasonal human coronaviruses associated with the common cold in the COVID-19 era," *Microorganisms*, vol. 11, no. 2, Art. no. 445, 2023, doi: 10.3390/microorganisms11020445.

[11] J. Huynh, K. Mos, A. Kesson, J. R. Egan, and N. Singhal, "Believing bocavirus: A rare cause of life-threatening acute respiratory distress syndrome requiring extracorporeal membrane oxygenation," *Journal of Paediatrics and Child Health*, vol. 56, no. 10, p. 1634, 2020, doi: 10.1111/jpc.14803.

[12] K. Ji, J. Sun, Y. Yan, *et al.*, "Epidemiologic and clinical characteristics of human bocavirus infection in infants and young children suffering with community acquired pneumonia in Ningxia, China," *Virology Journal*, vol. 18, no. 1, 2021, doi: 10.1186/s12985-021-01682-1.

[13] A. D. Kaye, E. M. Cornett, K. C. Brondeel, *et al.*, "Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment," *Best Practice & Research Clinical Anaesthesiology*, vol. 35, no. 3, p. 269, 2020, doi: 10.1016/j.bpa.2020.12.003.
[14] E. J. Lee, H. S. Kim, H. S. Kim, *et al.*, "Human bocavirus in Korean children with gastroenteritis and respiratory tract infections," *BioMed Research International*, vol. 2016, Art. no. 7507895, 2016, doi: 10.1155/2016/7507895.
[15] S. Lekana-Douki, S. Behillil, V. Enouf, E. M. Leroy, and N. Berthet, "Detection of human bocavirus-1 in both nasal and stool specimens from children under 5 years old with influenza-like illnesses or diarrhea in Gabon," *BMC Research Notes*, vol. 11, no. 1, 2018, doi: 10.1186/s13104-018-3605-1.
[16] J. Liao, Z. Yang, Y. He, *et al.*, "Respiratory tract infection of fatal severe human bocavirus 1 in a 13-month-old child: A case report and literature review," *Frontiers in Pediatrics*, vol. 10, 2022, doi: 10.3389/fped.2022.949817.
[17] W. Liu, Q. Liu, D. Chen, *et al.*, "Epidemiology of HBoV1 infection and relationship with meteorological conditions in hospitalized pediatric patients with acute respiratory illness: A 7-year study in a subtropical region," *BMC Infectious Diseases*, vol. 18, no. 1, 2018, doi: 10.1186/s12879-018-3225-3.
[18] S. Ljubin-Sternak, A. Slović, M. Mijač, *et al.*, "Prevalence and molecular characterization of human bocavirus detected in Croatian children with respiratory infection," *Viruses*, vol. 13, no. 9, Art. no. 1728, 2021, doi: 10.3390/v13091728.
[19] R. A. López-Astacio, O. F. Adu, H. Lee, S. Hafenstein, and C. R. Parrish, "The structures and functions of parvovirus capsids and missing pieces: The viral DNA and its packaging, asymmetrical features, nonprotein components, and receptor or antibody binding and interactions," *Journal of Virology*, vol. 97, no. 7, 2023, doi: 10.1128/JVI.00161-23.
[20] N. Madi and A. Al-Adwani, "Human bocavirus (HBoV) in Kuwait: Molecular epidemiology and clinical outcome of the virus among patients with respiratory diseases," *Journal of Medical Microbiology*, vol. 69, no. 7, p. 1005, 2020, doi: 10.1099/jmm.0.001219.
[21] J. Magden, L. Kääriäinen, and T. Ahola, "Inhibitors of virus replication: Recent developments and prospects," *Applied Microbiology and Biotechnology*, vol. 66, no. 6, p. 612, 2004, doi: 10.1007/s00253-004-1783-3.
[22] E. Manaresi and G. Gallinella, "Advances in the development of antiviral strategies against parvovirus B19," *Viruses*, vol. 11, no. 7, Art. no. 659, 2019, doi: 10.3390/v11070659.
[23] A. Mukherjee and P. Bagchi, "Host cell–virus interaction 2.0: Viral stratagems of immune evasion, host cellular responses and antiviral counterattacks," *Viruses*, vol. 15, no. 8, Art. no. 1717, 2023. [Online]. Available: https://www.mdpi.com/1999-4915/15/8/1717
[24] J. R. Otieno, J. L. Cherry, D. Spiro, M. I. Nelson, and N. S. Trovão, "Origins and evolution of seasonal human coronaviruses," *Viruses*, vol. 14, no. 7, Art. no. 1551, 2022, doi: 10.3390/v14071551.
[25] K. Parker, H. Wood, J. A. Russell, *et al.*, "Development and optimization of an unbiased, metagenomics-based pathogen detection workflow for infectious disease and biosurveillance applications," *Tropical Medicine and Infectious Disease*, vol. 8, no. 2, Art. no. 121, 2023, doi: 10.3390/tropicalmed8020121.
[26] M. P. Ś. Pluta, "Klinische Pädiatrie," *Klinische Pädiatrie*, 2025, doi: 10.1055/s-00000034.
[27] S. Ranjan, K. Vashishth, K. Sak, and H. S. Tuli, "The emergence of mpox: Epidemiology and current therapeutic options," *Current Pharmacology Reports*, vol. 9, no. 3, p. 144, 2023, doi: 10.1007/s40495-023-00318-y.
[28] N. M. Rizk, S. Abd-Elmaksoud, T. M. Farid, M. M. A. Abohashish, A. Z. Al-Herrawy, and I. A. Hamza, "Etiology of diarrheal disease among children under 5 years in Egypt: A high incidence of human bocavirus," *Journal of the Egyptian Public Health Association*, vol. 96, no. 1, 2021, doi: 10.1186/s42506-021-00084-z.
[29] G. Rong, Y. Zheng, X. Li, *et al.*, "A high-throughput fully automatic biosensing platform for efficient COVID-19 detection," *Biosensors and Bioelectronics*, vol. 220, Art. no. 114861, 2022, doi: 10.1016/j.bios.2022.114861.
[30] D. Schoeman, B. Gordon, and B. C. Fielding, "Coronaviruses," in *Elsevier eBooks*. Elsevier BV, 2021, p. 241, doi: 10.1016/B978-0-12-818731-9.00052-5.
[31] L. Shao, W. Shen, S. Wang, and J. Qiu, "Recent advances in molecular biology of human bocavirus 1 and its applications," *Frontiers in Microbiology*, vol. 12, 2021, doi: 10.3389/fmicb.2021.696604.
[32] V. Thawani and C. Bajait, "Role of zinc in pediatric diarrhea," *Indian Journal of Pharmacology*, vol. 43, no. 3, p. 232, 2011, doi: 10.4103/0253-7613.81495.
[33] S. Trapani, A. Caporizzi, S. Ricci, and G. Indolfi, "Human bocavirus in childhood: A true respiratory pathogen or a 'passenger' virus? A comprehensive review," *Microorganisms*, vol. 11, no. 5, Art. no. 1243, 2023, doi: 10.3390/microorganisms11051243.

[34] W. Wang, R. Guan, Z. Liu, *et al.*, "Epidemiologic and clinical characteristics of human bocavirus infection in children hospitalized for acute respiratory tract infection in Qingdao, China," *Frontiers in Microbiology*, vol. 13, 2022, doi: 10.3389/fmicb.2022.935688.
[35] F. Zech, C. Jung, T. Jacob, and F. Kirchhoff, "Causes and consequences of coronavirus spike protein variability," *Preprints*, Jan. 3, 2024, doi: 10.20944/preprints202401.0230.v1.
[36] X. Zhang, J. Zheng, L.-H. Zhang, and H. Xu, "Human bocavirus-1 screening in infants with acute lower respiratory tract infection," *Journal of International Medical Research*, vol. 49, no. 8, 2021, doi: 10.1177/03000605211027739.
.